Next Article in Journal
Biological Functions of HMGN Chromosomal Proteins
Next Article in Special Issue
Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection
Previous Article in Journal
Comparison of The Sorption Kinetics of Lead(II) and Zinc(II) on Titanium Phosphate Ion-Exchanger
Previous Article in Special Issue
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Article

Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis

1
Department of Health Sciences, University of Florence, 50139 Florence, Italy
2
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital-Strada di Fiume 447, 34149 Trieste, Italy
3
Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK
4
Unit of Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Viale Bracci-Policlinico “Le Scotte”, 53100 Siena, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(2), 448; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21020448
Received: 24 November 2019 / Revised: 31 December 2019 / Accepted: 8 January 2020 / Published: 10 January 2020
(This article belongs to the Special Issue Cancer Immunotherapy Using Checkpoint Inhibitors: Future Directions)
Immunotherapy has recently changed the treatment of several cancers. We performed a literature-based meta-analysis of randomised controlled trials to assess the efficacy of the novel immune checkpoint inhibitors (ICIs) in metastatic gastric cancer. The main outcome was overall survival. Based on age (cut-off agreed at 65 years), tumour location (gastric vs. gastro-oesophageal junction), programmed death-ligand 1 (PD-L1) status, sex and Eastern Cooperative Oncology Group (ECOG) status (1 vs. 0), we scheduled a subgroup analysis for the overall survival. Three studies were included in the analysis for a total of 1456 cases (811 cases were in the experimental group and 645 cases in the control group). The pooled analysis showed improved overall survival in the experimental arm in the absence of statistical significance (hazard ratio (HR) = 0.87, 95% CI: 0.64–1.18; p = 0.37). The subgroup of patients with PD-L1-positive tumours (HR = 0.82 vs. 1.04) and gastro-oesophageal junction cancer (HR = 0.82 vs. 1.04) showed a statistically significant advantage of overall survival. This study supports the efficacy of immune checkpoint inhibitors in the subgroup of patients with metastatic gastric cancer with PD-L1-positive and gastro-oesophageal junction tumour location. Future studies are needed with the aim of identifying reliable predictive biomarkers of ICI efficacy. View Full-Text
Keywords: nivolumab; PD-1; PD-L1; immunotherapy; gastric cancer nivolumab; PD-1; PD-L1; immunotherapy; gastric cancer
Show Figures

Figure 1

MDPI and ACS Style

Roviello, G.; Corona, S.P.; D’Angelo, A.; Rosellini, P.; Nobili, S.; Mini, E. Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. Int. J. Mol. Sci. 2020, 21, 448. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21020448

AMA Style

Roviello G, Corona SP, D’Angelo A, Rosellini P, Nobili S, Mini E. Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. International Journal of Molecular Sciences. 2020; 21(2):448. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21020448

Chicago/Turabian Style

Roviello, Giandomenico, Silvia P. Corona, Alberto D’Angelo, Pietro Rosellini, Stefania Nobili, and Enrico Mini. 2020. "Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis" International Journal of Molecular Sciences 21, no. 2: 448. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21020448

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop